FAST NEWS: Legend Biotech Terminates New Drug Trial Lacking Clinical Benefit
The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), has terminated its Phase 1 Clinical Trial under the Investigational New Drug (IND) application for LB1901, due to…
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
1548.HK LEGN.US
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Legend Holdings shows diversification isn’t always a winning formula
3396.HK
Discover hidden China stock gems in our weekly newsletter